Industry | 制造业 | ||||||||||||||||||||||||
Company Introduction | 努力推动中国制造走向世界——集团在注射制剂等复杂制剂用辅料的技术研究和标准提升方面走在了全国前列,对中国医药工业的发展起到了引领和促进作用,药用辅料产品畅销海内外;集团在高级合成润滑基础油醚类、酯类及醚酯类产品在军事、航空、航海、汽车、空调、特种机械等领域得到广泛应用,且远销欧美等发达国家和地区,是具有国际竞争力的中国第一品牌;其他业务板块领域也以技术质量领先为基础、为客户创造价值为抓手,在细分市场获得普遍赞誉。 用创新守护生命健康——集团以市场为导向,科技创新为根本。集团研究院拥有130多人的研发创新队伍,先后创建了国家药品监督管理局—药物制剂及辅料研究与评价重点实验室、江苏省水溶性药用辅料工程技术研究中心、江苏省外国专家工作室、企业博士后创新实践基地、高校研究生工作站等科技创新平台,是集团各业务板块成长、发展、壮大的不竭源泉。 用发展成就社会价值——集团以细分领域产品品类和职能业务模块为基本单位,设立了多家子公司,分别承载集团技术与产品创新、生产经营与运作功能,以实现将细分领域产品做精、做优,细分领域市场做强、做大的目标,同时不断为客户、员工、股东、供应商、社区等利益相关方创造价值。 | ||||||||||||||||||||||||
Main Business | 药用辅料及合成润滑基础油产品的研发、生产和销售。 | ||||||||||||||||||||||||
Legal Representative | 吴仁荣 | ||||||||||||||||||||||||
Top Executives |
|
||||||||||||||||||||||||
Top 5 Shareholder |
|
||||||||||||||||||||||||
Company Secretary | 唐群松 | ||||||||||||||||||||||||
Solicitors | 北京市君合律师事务所 | ||||||||||||||||||||||||
Auditors | 信永中和会计师事务所(特殊普通合伙) | ||||||||||||||||||||||||
Tel No | 025-85732322 | ||||||||||||||||||||||||
Fax No | 025-83172915 | ||||||||||||||||||||||||
Website | www.wellnj.com | ||||||||||||||||||||||||
wellyy@wellnj.com | |||||||||||||||||||||||||
Company Address |
|
||||||||||||||||||||||||
Listing Date | 30/01/2019 | ||||||||||||||||||||||||
Shares Capital |
|
||||||||||||||||||||||||
EPS(RMB)* | ¥ 0.830 | ||||||||||||||||||||||||
DPS(RMB)* | ¥ 0.300 | ||||||||||||||||||||||||
NBV Per Share(RMB)* | ¥ 11.698 | ||||||||||||||||||||||||
Market Capitalization(RMB) | 3.276B |
Only Chinese content is avaliable | |
N
/
N
: Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SH-HK Ex-Northbound trade (sell only)
|
|
N
/
N
: Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
|
|
* | Unadjusted Data |
Information provided by: etnet | ||
Terms and Conditions |
Risk Disclosure: |
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone. |
Disclaimer: |
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources, Nanyang Commercial Bank Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information. |